Aurora CannabisACB +1.07%59 Receivables Turnover is 0.88 as of Mar. 2026. GuruFocus rates ACB with a GF Score™ of 59/100 and a GF Value™ of $4.15 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 943 Drug Manufacturers companies, Aurora Cannabis ranks better than 76.88% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Aurora Cannabis's Revenue for the
three
months ended in Mar. 2026 was $27.7 Mil. Aurora Cannabis's average Accounts Receivable for the
three
months ended in Mar. 2026 was $31.3 Mil.
Hence, Aurora Cannabis's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.88.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Aurora Cannabis Receivables Turnover Related Terms
Aurora Cannabis Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Aurora Cannabis's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Cannabis Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Aurora Cannabis's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurora Cannabis (ACB) has a Receivables Turnover of 0.88 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aurora Cannabis and its competitors. According to the industry distribution chart, Aurora Cannabis ranks #218 out of 943 companies in the Drug Manufacturers industry, placing it in the top 23.1%.
Is Aurora Cannabis' Receivables Turnover too high?
Aurora Cannabis' current Receivables Turnover is 0.88. The Drug Manufacturers industry median Receivables Turnover is 5.07. Aurora Cannabis' value of 0.88 is 82.6% below this industry median. Based on the distribution chart, Aurora Cannabis ranks #218 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aurora Cannabis has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Cannabis' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurora Cannabis ranks #218 out of 943 companies for Receivables Turnover. This places Aurora Cannabis in the top 23% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Aurora Cannabis' value of 0.88 is 82.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Cannabis's current Receivables Turnover of 0.88 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aurora Cannabis and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Cannabis's current Receivables Turnover is 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Aurora Cannabis (ACB) is currently considered Possible Value Trap. The stock's GF Value™ is $4.15, compared to a current price of $2.86 — trading 31.1% below its estimated fair value. The current Receivables Turnover is 0.88 and 82.6% below the Drug Manufacturers industry median of 5.07. Aurora Cannabis' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Aurora Cannabis (ACB), the current Receivables Turnover is 0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Cannabis (ACB) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Cannabis stock appears to be undervalued.
The current stock price of $2.86 is trading 31.1% below its estimated GF Value™ of $4.15.
GuruFocus considers Aurora Cannabis to be Possible Value Trap.
Key valuation signals for ACB:
Receivables Turnover: 0.88
GF Value™: $4.15 vs. price of $2.86 (31.1% below fair value)
Industry Position: 82.6% below the Drug Manufacturers median (#218 of 943)
No single metric tells the full story. See the ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
59GF Score
Get the complete analysis for ACB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACB has been successfully added to your 
